Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03282344 · ClinicalTrials.gov registry record · Phase 2
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma
A Phase 2 study of Sarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 2
- Study locations
NCT03282344: Active Phase 2 study of Sarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03282344 is a Phase 2 study of Sarcoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 88 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03282344, a Phase 2 study of Sarcoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to test any good and bad effects of the combination of study drugs called NKTR-214 and nivolumab.
Primary Outcome
Primary Response Criteria (RECIST 1.1) Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this inc
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG NKTR-214
Study Locations (2)
New York
- Memorial Sloan Kettering Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort) - New York
Texas
- MD Anderson Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2017-09-12 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT03282344 still lists
NCT03282344 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03282344 reports a single indexed study location in New York, Texas.
Frequently Asked Questions
What is clinical trial NCT03282344 about?
NCT03282344 is a clinical study titled "A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma". The purpose of this study is to test any good and bad effects of the combination of study drugs called NKTR-214 and nivolumab.
What is the current status of trial NCT03282344?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2017-09-12. Estimated completion is 2026-09.
What conditions does trial NCT03282344 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT03282344?
The interventions under investigation include: Nivolumab (DRUG), NKTR-214 (DRUG).
Who is sponsoring clinical trial NCT03282344?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03282344 being conducted?
This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03282344's enrollment target sits among peer trials
88 46th of 122 higher than 77 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy